Skip Navigation

Phase I/II clinical trial of regorafenib plus durvalumab MEDI4736 in patients with chemo refractory advanced biliary tract cancers

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04781192

Study #:
STUDY00146841

Start Date:
Feb 25, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04781192

View Complete Trial Details & Eligibility at ClinicalTrials.gov